Liver Transplant for Sclerosing Cholangitis: Long-Term Survival and the Cancer Conundrum
A major French national cohort study provides critical long-term data on patient and graft survival following liver transplantation for primary sclerosing cholangitis (PSC), a complex chronic liver disease. Analyzing 571 adult patients transplanted over three decades, the research found robust 5-year and 10-year patient survival rates of 88.2% and 81.2%, respectively. However, the study highlights malignancy as the predominant threat, with recurrent cholangiocellular carcinoma (CCA) being a leading cause of early death and colorectal cancer emerging as a significant late-term risk. Key factors associated with improved late outcomes included the use of tacrolimus and younger age at transplantation, while a bilio-digestive anastomosis was linked to higher mortality.
Study Significance: This large-scale hepatology study underscores that while liver transplantation is a highly effective treatment for end-stage PSC, the long-term management strategy must aggressively address cancer surveillance. For gastroenterologists and transplant hepatologists, the findings mandate a dual focus: optimizing pre-transplant screening for cholangiocellular carcinoma and implementing rigorous, lifelong post-transplant colonoscopy protocols for colorectal cancer detection. The identification of specific protective and risk factors provides a data-driven framework for refining immunosuppression regimens and surgical approaches to further improve outcomes in this challenging patient population.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
